Save up -80% on Ruxolitinib

Note: this is a drug discount program, not an insurance plan.
RX BIN: 015558RX PCN: HTGroup ID: DDN6600Card Holder ID: DDN6600
Pharmacists and Patients support.

2019 Price of Jakafi

$12,988.2960 tablets/10 mg
price without discount in nearest pharmacy. Price may vary.

Claim your free Ruxolitinib discount card

We offer free Ruxolitinib coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Ruxolitinib every time. What are you waiting for? Claim your prescription drug card now!

Walgreens pharmacy
Walgreens pharmacy
CVS pharmacy
CVS pharmacy
Walmart pharmacy
Walmart pharmacy
Ride AID pharmacy
Ride AID pharmacy
CVS Target pharmacy
CVS Target pharmacy
Kroger pharmacy
Kroger pharmacy

Get your Prescription


It’s safe and free


Buy drugs in pharmacy

save money

Save money each time

Ruxolitinib volume of distribution

Terminal phase volume of distribution, 15 mg, healthy subject = 76.6 L.

RX Prescription
Ask Your therapeut before taking any drugs.

About RX24Drugs

2018 Statistics

discount card

Discount Cards 16,000+


Clients Benefit 29%


Total savings $4,735,080

What is Ruxolitinib

Ruxolitinib is a janus-associated kinase inhibitor indicated to treat bone marrow cancer, specifically intermediate or high-risk myelofibrosis. FDA approved on November 16, 2011.

Ruxolitinib mechanism of action

Ruxolitinib is a kinase inhibitor that is selective for the Janus Associated Kinases (JAK) 1 and 2. These kinases are responsible for the mediation of cytokine and growth factor signalling which in turn effect immune function and hematopoiesis. The signalling process involves signal transducers and transcription activators (STAT) which modulate gene expression. Patients with myelofibrosis have abnormal JAK1 and JAK2 activity thus ruxolitinib works to regulate this.

Dosage forms of Ruxolitinib

Tabletoral10 mg/1
Tabletoral15 mg/1
Tabletoral20 mg/1

Prescription Generics


International Brands



INCB018424 INCB424


Incyte Corporation

CAS number






Affected organisms

Humans and other mammals

Indication of Ruxolitinib

Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis.[Lexicomp]Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).

Toxicity of Ruxolitinib

Thrombocytopenia was the dose-limiting toxicity.

RX24 Drugs Disclaimer: consult your healthcare provider before buying a Ruxolitinib on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.

Get lower price on Ruxolitinib now!